康缘品牌怎么样 申请店铺

我要投票 康缘在中草药行业中的票数:242 更新时间:2025-05-10
康缘是哪个国家的品牌?「康缘」是 江苏康缘药业股份有限公司 旗下著名品牌。该品牌发源于江苏,由创始人肖伟在1996期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力康缘品牌出海!将品牌入驻外推网,定制康缘品牌推广信息,可以显著提高康缘产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

康缘怎么样

充满活力的创新型制药企业--江苏康缘药业股份有限公司是一家集中药研发、生产、贸易为一体的大型中药企业,是国家中药现代化示范企业、国家重点高新技术企业、国内A股上市公司、国家创新型企业,全国制药工业百强企业,获国家“质量管理先进企业”,“守合同重信用企业”等荣誉称号,“康缘”商标为国家驰名商标。

公司坚持以科研创新为先导,不断提升企业自主创新实力。企业设立博士后科研工作站、江苏省院士工作站,成立康缘现代中药研究院,拥有一支包括6名博士后、12名博士、80余名硕士在内的180多名科研人员组成的研究队伍;先后与中国医学科学院药物研究所、中科院上海有机化学研究所、大连工业大学等科研院所联合建立了十余个共建实验室,并在美国建立了创新药物研发公司,自主创新能力位居国内同行前列,发明专利授权量在同行业中名列前茅。2002年康缘药业被批准设立博士后科研工作站,2005年公司研发中心被认定为国家级企业技术中心。2010年1月康缘研究院被国家科技部批准建设“中药制药过程新技术国家重点实验室”,进入我国中医药创新体系国家队行列。

康缘药业拥有国内最大的智能化中药材提取生产线,具有年处理生药材10000吨的能力;拥有通过国家GMP验证的制剂车间,配套完善的备料中心、质量检测中心、动力中心、智能管理中心,设有硬胶囊、软胶囊、小容量注射剂、冻干粉针剂等十三条最先进的生产线,具备年生产硬胶囊12亿粒、软胶囊3.4亿粒、口服液1亿支、小容量注射剂5亿支、冻干粉针剂600万支、片剂15亿片、颗粒剂1000吨的能力。

康缘药业全力推行专业化、学术化营销,建立了一支高素质、专业化1600余人的营销队伍,在全国29个省市建立了34个销售分公司、226多个中心办事处,与全国146家医药商业公司建立了长期稳定的业务关系,产品覆盖近7000家县级以上医疗单位。

Jiangsu Kangyuan Pharmaceutical Co., Ltd., a dynamic and innovative pharmaceutical enterprise, is a large-scale Chinese medicine enterprise integrating research and development, production and trade of traditional Chinese medicine. It is a national modern demonstration enterprise of traditional Chinese medicine, a national key high-tech enterprise, A-share listed company, a national innovative enterprise, and one of the top 100 pharmaceutical enterprises in China, It has won the honorary titles of "advanced quality management enterprise", "contract abiding and trustworthy enterprise" and "Kangyuan" trademark is a national well-known trademark. The company adheres to scientific research and innovation as the guide, and constantly improves the independent innovation strength of the enterprise. The company has set up postdoctoral research station, Jiangsu academician workstation, and Kangyuan modern Chinese Medicine Research Institute. It has a research team of more than 180 researchers, including 6 postdoctoral, 12 doctors, and more than 80 masters. It has been jointly built with the Institute of medicine of Chinese Academy of Medical Sciences, Shanghai Institute of organic chemistry of Chinese Academy of Sciences, Dalian University of technology and other research institutes More than ten co built laboratories have been set up, and innovative drug R & D companies have been established in the United States. The independent innovation ability ranks in the forefront of domestic peers, and the amount of invention patent authorization ranks first in the same industry. In 2002, Kangyuan pharmaceutical was approved to set up a postdoctoral research workstation, and in 2005, the company's R & D center was recognized as a national enterprise technology center. In January 2010, Kangyuan Research Institute was approved by the Ministry of science and technology of the people's Republic of China to build the "National Key Laboratory of new technology in the pharmaceutical process of traditional Chinese medicine", and entered the ranks of the national team of Chinese medicine innovation system. Kangyuan Pharmaceutical Co., Ltd. has the largest intelligent production line of Chinese herbal medicine extraction in China, with an annual capacity of 10000 tons of raw herbs. It has a preparation workshop certified by the national GMP, a complete set of material preparation center, quality inspection center, power center, intelligent management center, and 13 most advanced production lines, including hard capsule, soft capsule, small volume injection, freeze-dried powder injection, It has the annual production capacity of 1.2 billion hard capsules, 340 million soft capsules, 100 million oral liquids, 500 million small volume injections, 6 million lyophilized powder injections, 1.5 billion tablets and 1000 tons of granules. Kangyuan pharmaceutical industry has made great efforts to promote professional and academic marketing, established a high-quality and professional marketing team of more than 1600 people, established 34 sales branches and more than 226 central offices in 29 provinces and cities across the country, established long-term and stable business relations with 146 pharmaceutical commercial companies across the country, with products covering nearly 7000 medical units above the county level.

本文链接: https://brand.waitui.com/0310949a5.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

奥乐齐昆山首店正式开业

36氪获悉,5月10日,奥乐齐ALDI位于昆山的首家门店正式开业。这是奥乐齐在苏州、无锡成功开设两家门店且大受本地居民欢迎与认可之后,于江苏地区布局的又一重要里程碑。短时间内在苏锡昆“连开三店”,不仅凸显出奥乐齐广受当地受众认可,亦彰显了其对本地消费市场的坚定信心,更标志着品牌在江苏市场战略布局的进一步拓展与深化。

2小时前

浙江大学董雪兵:强化产业创新协同 发挥区域战略叠加效应

5月9日,2025长三角粤港澳国家战略联动发展论坛在广州举行。论坛前夕,上海证券报记者就如何深化区域联动等问题,采访浙江大学区域协调发展研究中心副主任董雪兵。董雪兵认为,长三角、粤港澳大湾区等重点区域应在服务国家战略需求的基础上,发挥战略叠加效应,实现进一步联动发展。以产业协同为例,长三角和粤港澳大湾区可以发挥各自优势,围绕生物医药、人工智能、集成电路等双方均具优势的领域,开展创新链、产业链、供应链和价值链的空间融合,共同打造全国领先的产业集群。(上证报)

2小时前

永达股份:子公司部分产品应用于机器人领域,业务规模尚小

永达股份(001239)5月9日在业绩说明会上表示,公司控股子公司江苏金源高端装备有限公司部分产品应用于机器人领域,但在此领域的业务规模尚小。(e公司)

2小时前

《中国企业海外传播力分析报告(2024)》正式发布

《中国企业海外传播力分析报告(2024)》在于浙江德清举办的2025世界品牌莫干山大会上正式发布。《报告》发现,中国企业的国际传播及形象打造策略获得实效。中国企业早期的形象宣传多集中于技术革新的宏大叙事或文化符号的堆叠,而当前实践更强调多维度资源的整合。中国企业的海外形象建构策略正在经历从“单一功能输出”向“多维价值融合”的转型,其核心在于通过技术、文化与社会责任的动态协同,构建更具韧性的品牌叙事。例如,作为中国全球化企业代表之一,海信将“环境、社会、治理”(ESG)理念深度融入全球化发展,构建了独具特色的国际传播模式。(财联社)

2小时前

烨隆股份撤回上市申请

上海证券报记者从上交所获悉,过会已一年多的无锡烨隆精密机械股份有限公司5月8日撤回上市申请,上交所主板IPO终止。(上证报)

2小时前

本页详细列出关于康缘的品牌信息,含品牌所属公司介绍,康缘所处行业的品牌地位及优势。
咨询